{"id":94283,"date":"2021-06-07T22:00:00","date_gmt":"2021-06-07T12:00:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2021\/06\/07\/study-of-paxalisib-in-primary-cns-lymphoma-at-dana-farber-cancer-institute-enrols-first-patient\/"},"modified":"2021-06-07T22:00:00","modified_gmt":"2021-06-07T12:00:00","slug":"study-of-paxalisib-in-primary-cns-lymphoma-at-dana-farber-cancer-institute-enrols-first-patient","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2021\/06\/07\/study-of-paxalisib-in-primary-cns-lymphoma-at-dana-farber-cancer-institute-enrols-first-patient\/","title":{"rendered":"Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1313895\/KaziaLogo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"xn-location\">SYDNEY<\/span>, <span class=\"xn-chron\">June 7, 2021<\/span> \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia&#8217;s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p><b>Key Points<\/b><\/p>\n<ul type=\"disc\">\n<li>Lymphoma is a cancer of white blood cells. It occurs in the lymphatic system and can spread almost anywhere in the body; primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system <\/li>\n<li>The PI3K inhibitor class, to which paxalisib belongs, is well validated in lymphoma outside the brain; three of the four FDA-approved PI3K inhibitors are treatments for forms of lymphoma, but they are assumed ineffective for PCNSL since they cannot cross the blood-brain barrier <\/li>\n<li>DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL, and is expected to recruit up to 25 patients, taking up to 2 years to complete <\/li>\n<li>Kazia will provide support including study drug and a financial grant<\/li>\n<\/ul>\n<p>Dana-Farber Cancer Institute (DFCI) is a world-leading cancer treatment and research centre, based in <span class=\"xn-location\">Boston, Massachusetts<\/span>. It is a principal teaching affiliate of <span class=\"xn-org\">Harvard Medical School<\/span> and has been designated a Comprehensive Cancer Center by the US National Cancer Institute. DFCI participates in as many as 600 clinical trials at any given time and has been an important contributor to the development of many important new cancer therapies. <\/p>\n<p>The Principal Investigator for the study, Dr Lakshmi Nayak, commented &#034;our center has a strong research focus in primary CNS lymphoma. We are very interested to explore the potential for a brain-penetrant PI3K inhibitor in this disease. Patient outcomes in PCNSL remain far from optimal, and there is a pressing need for new treatment options.&#034;<\/p>\n<p>Kazia CEO, Dr <span class=\"xn-person\">James Garner<\/span>, commented, &#034;we are delighted to see this study underway, and congratulate Dr Nayak and her team on getting it launched. With paxalisib now in an international pivotal study for glioblastoma, we are increasingly focused on identifying other groups of patients who may benefit from the drug. There is a very sound rationale to explore PCNSL in this disease, and we are looking forward to seeing the study progress.&#034;<\/p>\n<p><b>Primary CNS Lymphoma<\/b><\/p>\n<p>Lymphoma is a haematological malignancy (blood cancer) that originates from lymphocytes, a type of white blood cell involved in the immune system. PCNSL is a specific form of the disease that originates in the brain and central nervous system.<\/p>\n<p>Three of the four PI3K inhibitors approved by the US Food and Drug Administration (FDA) are treatments for various forms of lymphoma, provide a strong validation for PI3K as a target in this disease. Paxalisib is the only PI3K inhibitor in mainstream development with the ability to penetrate the blood-brain barrier, and as such has a unique rationale for development in PCNSL.<\/p>\n<p>The incidence of PCNSL has been increasing with time. Patients are typically in their 60s or older, and the disease is slightly more common in men.<sup>[1]<\/sup> The mainstays of treatment comprise chemotherapy and radiotherapy, but recurrence is common and only approximately 30% of patients remain alive five years after diagnosis.<sup>[2]<\/sup> Many of the drugs used to treat lymphoma elsewhere in the body are ineffective in PCNSL due to their inability to cross the blood-brain barrier.<\/p>\n<p><b>DFCI Clinical Trial<\/b><\/p>\n<p>The CNS Lymphoma Center (CNSLC) at Dana-Farber \/ Brigham and Women&#8217;s Cancer Center is the first centre of its kind in the world dedicated to providing comprehensive care and research for patients with primary or secondary CNS lymphoma. With the most advanced treatment options available \u2014 including surgery, chemotherapy, stem cell transplant, radiation therapy, immunotherapy, and targeted therapies, and with extensive clinical trial options \u2014 CNSLC is uniquely qualified to treat patients with CNS lymphoma and advance the outcome of patients with these tumors.<\/p>\n<p>The principal investigator for the study is Dr Lakshmi Nayak, Director of the CNS Lymphoma Center at Dana-Farber Cancer Institute. Dr Nayak is an Assistant Professor of Neurology at <span class=\"xn-org\">Harvard Medical School<\/span> and a board-certified neuro-oncologist. Her research interests focus on metastatic brain cancer, glioblastoma, and PCNSL, and she is extensively published in the field of brain cancer. She has been an investigator for multiple clinical trials of experimental drugs in this disease area.<\/p>\n<p><b>Paxalisib Clinical Program<\/b><\/p>\n<p>The initiation of this trial in PCNSL brings the number of ongoing clinical studies of paxalisib in brain cancer to eight. <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tbody>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Sponsor<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Phase<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Indication<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Registration<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Kazia Therapeutics<\/p>\n<p><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">II<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Glioblastoma<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT03522298<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Global Coalition for <br \/>Adaptive Research<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">II \/ III<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Glioblastoma<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT03970447<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Alliance for Clinical Trials <br \/>in Oncology<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">II<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Brain metastases<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT03994796<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Dana-Farber Cancer <br \/>Institute<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">II<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Breast cancer brain metastases<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">(<i>with Herceptin<\/i>)<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT03765983<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Dana-Farber Cancer <br \/>Institute<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">II<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Primary CNS lymphoma<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT04906096<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Pacific Pediatric Neuro-<br \/>Oncology Consortium<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">N\/A<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">DIPG &#038; DMGs<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">TBD<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">St Jude Children&#8217;s<br \/>Research Hospital<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">I<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">DIPG (childhood brain cancer)<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT03696355<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Memorial Sloan Kettering <br \/>Cancer Center<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">I<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Brain metastases<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">(<i>with radiotherapy<\/i>)<\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT04192981<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&#160;<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tbody>\n<tr>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><sup>[1]<\/sup>&#160;J Rubenstein et al. (2008) <i>Leuk Lymphoma<\/i> 49(0 1):43-51<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><sup>[2]<\/sup>&#160;MS Shiels et al. (2016) <i>Br J Haematol<\/i>. 174(3):417-424<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>About Kazia Therapeutics Limited <\/b><\/p>\n<p>Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in <span class=\"xn-location\">Sydney, Australia<\/span>. <\/p>\n<p>Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K \/ Akt \/ mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in <span class=\"xn-chron\">January 2021<\/span>. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">February 2018<\/span>, and Fast Track Designation for glioblastoma by the US FDA in <span class=\"xn-chron\">August 2020<\/span>. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in <span class=\"xn-chron\">August 2020<\/span>.<\/p>\n<p>Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in <span class=\"xn-chron\">April 2021<\/span>. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study is expected to begin in CY2021. <\/p>\n<p>For more information, please visit <a target=\"_blank\" href=\"http:\/\/www.kaziatherapeutics.com\/\" rel=\"nofollow\">www.kaziatherapeutics.com<\/a> or follow us on Twitter @KaziaTx.<\/p>\n<p>This document was authorized for release to the ASX by <span class=\"xn-person\">James Garner<\/span>, Chief Executive Officer, Managing Director.<\/p>\n<p><b>CLINICAL TRIAL SUMMARY<\/b><\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tbody>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Study Title<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Paxalisib (GDC-0084) In Recurrent or Refractory PCNSL<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Phase of Development<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Phase II<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Investigational Product<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Paxalisib (GDC-0084)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Disease Area<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Recurrent or refractory primary central nervous system <br \/>lymphoma (PCNSL)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Registration<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">NCT04906096<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Principal Investigator<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Associate Professor Lakshmi Nayak <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i>Dana-Farber Cancer Institute, Boston, MA<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Study Description<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">This is an open-label, phase II study to determine the efficacy of <br \/>paxalisib (GDC-0084) in patients with recurrent or refractory <br \/>primary central nervous system lymphoma (R\/R PCNSL).<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Number of Subjects<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">25 patients<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Study Design<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">This is an open-label, single-arm study. Eligible patients with R\/R <br \/>PCNSL will be administered paxalisib as monotherapy for up to <br \/>24 months, in dosing regimen similar to that used for other adult <br \/>brain cancers.<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Results will evaluated against historical controls appropriate to <br \/>the enrolled patient population. <\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Patient Population<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Relapsed \/ refractory primary CNS lymphoma (R\/R PCNSL) <\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Endpoints<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">The primary endpoint of the study is overall response rate (ORR), <br \/>which measures the growth or shrinkage of tumour on a brain <br \/>scan during and after treatment.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Participating Centres<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Dana-Farber Cancer Institute \u2013 Boston, MA<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">Brigham &#038; Women&#8217;s Hospital \u2013 Boston, MA<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>Start Date<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">First Patient In: June 2021<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen7\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><b>End of Recruitment<\/b><\/span><\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen8\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Last Patient In (anticipated): 1H CY 2023<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&#160;<\/p>\n<p>&#160;<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, June 7, 2021 \/PRNewswire\/ &#8212; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/94283"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=94283"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/94283\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=94283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=94283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=94283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}